Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Labcorp Holdings Inc., 3 years.
Labcorp Holdings Inc.
Director
Adaptive Biotechnologies Corporation
Director
Fortrea Holdings Inc.
Director · Chief Executive Officer
Chief executive roles
Fortrea Holdings Inc.
· Chief Executive Officer
Until August 2025
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 14, 2026 | Fortrea Holdings Inc. | Option exercise | +148,536 | — | — |
| Mar 4, 2026 | Adaptive Biotechnologies Corporation | Grant or award | +15,625 | — | — |
| Feb 11, 2026 | Labcorp Holdings Inc. | Option exercise | +897 | — | — |
| Aug 11, 2025 | Fortrea Holdings Inc. | Open-market purchase | +32,500 | $6.26 | $203,450 |
| Aug 8, 2025 | Fortrea Holdings Inc. | Open-market purchase | +30,000 | $6.79 | $203,700 |
| May 14, 2025 | Fortrea Holdings Inc. | Option exercise | +7,282 | — | — |
| Mar 10, 2025 | Adaptive Biotechnologies Corporation | Option exercise | +50,000 | $4.07 | $203,500 |
| Mar 10, 2025 | Adaptive Biotechnologies Corporation | Open-market sale | −10,000 | $7.05 | $70,500 |
| Mar 4, 2025 | Adaptive Biotechnologies Corporation | Grant or award | +15,394 | — | — |
| Feb 6, 2025 | Labcorp Holdings Inc. | Option exercise | +944 | — | — |
| Jul 18, 2024 | Fortrea Holdings Inc. | Option exercise | +6,354 | — | — |
| Mar 12, 2024 | Adaptive Biotechnologies Corporation | Option exercise | +15,000 | $0.84 | $12,600 |
| Mar 4, 2024 | Adaptive Biotechnologies Corporation | Grant or award | +31,328 | — | — |
| Feb 7, 2024 | Labcorp Holdings Inc. | Option exercise | +947 | — | — |
| Dec 13, 2023 | Adaptive Biotechnologies Corporation | Option exercise | +100,000 | $0.84 | $84,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.